Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2012

View Archived Issues

New claudin-6-binding antibodies patented in Germany

Novel platinum(IV) complexes disclosed by Universidad Autonoma de Madrid

Allergan presents novel agents for ocular disorders

Galderma Pharma prepares new agent for rosacea

New human papillomavirus vaccines developed in China

Novel orexin OX receptor antagonists discovered at Actelion Pharmaceuticals

New mechanism of action reveals potential of salirasib to treat rare lung disorder

Two-gene signature predicts prognosis of previously untreated chronic lymphocytic leukemia

Shire and Sangamo BioSciences enter agreement for hemophilia therapeutics

IDRI contributes to Sabin Vaccine Institute's first-ever hookworm vaccine study

Boehringer Ingelheim selects Nanobody candidate from Ablynx alliance

ThromboGenics plans to resubmit ocriplasmin BLA for priority review

Study identifies new therapeutic target for refractory inflammation in COPD

Impax Pharmaceuticals gains U.S. rights to migraine therapy

FDA advisory committee sets review date for lorcaserin NDA resubmission

U.S. team designs new nanoparticle delivery systems to target chemotherapy to cancer cells

Phase III tuberculosis trial completes enrollment

Eusa Pharma acquires Asparec rights

Phase III lubiprostone study meets primary endpoint

New gene expression signature predicts outcome of patients with basal-like breast cancer

Boston Scientific launches Promus Element Plus stent system in Europe

Navidea Biopharmaceuticals receives CHMP advice on Lymphoseek MAA

Dosing begins in phase II AFN-1252 study in ABSSSI

WHO releases roadmap for work to eliminate neglected tropical diseases

Athersys receives grant to develop stem cell therapy for traumatic brain injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...